Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplantation (University Health Network)
- Development stage
- Unknown
- Lead developer
- University Health Network
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal
01
Overview
Fecal microbiota transplantation (FMT) is a microbial therapy involving the transfer of a fecal suspension from a healthy donor into the gastrointestinal tract of a patient. This specific preparation, developed and studied by the University Health Network (UHN) in Toronto, consists of a fecal slurry containing 50 grams of stool in 500ml of normal saline. The therapeutic mechanism is based on the restoration of a diverse and stable gut microbiota, which provides colonization resistance against *Clostridioides difficile*. By re-establishing ecological competition and restoring bile acid metabolism, FMT suppresses the overgrowth of *C. difficile* and the production of its toxins. It is primarily indicated for patients with recurrent or refractory *Clostridioides difficile* infection (CDI) who have failed standard antibiotic tapers.
- Other names
- Fecal microbiota transplantationFecal transplantFecal slurryFMT
Beyond the preview
Go deeper on fecal microbiota transplantation (University Health Network).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplantation (University Health Network).